| MYELODYSPLASTIC SYNDROME
Inqovi vs Rytelo
Side-by-side clinical, coverage, and cost comparison for myelodysplastic syndrome.Deep comparison between: Inqovi vs Rytelo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRytelo has a higher rate of injection site reactions vs Inqovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rytelo but not Inqovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inqovi
Rytelo
At A Glance
Oral
Once daily, Days 1-5 of each 28-day cycle
Nucleoside metabolic inhibitor
IV infusion
Every 4 weeks
Telomerase inhibitor
Indications
- MYELODYSPLASTIC SYNDROME
- Refractory anemias
- Refractory anemia with ringed sideroblasts
- Refractory anaemia with excess blasts
- Leukemia, Myelomonocytic, Chronic
- MYELODYSPLASTIC SYNDROME
Dosing
MYELODYSPLASTIC SYNDROME, Refractory anemias, Refractory anemia with ringed sideroblasts, Refractory anaemia with excess blasts, Leukemia, Myelomonocytic, Chronic 1 tablet (35 mg decitabine and 100 mg cedazuridine) orally once daily on Days 1 through 5 of each 28-day cycle, taken on an empty stomach; minimum of 4 cycles until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME 7.1 mg/kg administered as an intravenous infusion over 2 hours every 4 weeks; discontinue if no decrease in RBC transfusion burden after 24 weeks (6 doses) or if unacceptable toxicity occurs.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) fatigue, constipation, hemorrhage, myalgia, mucositis, arthralgia, nausea, dyspnea, diarrhea, rash, dizziness, febrile neutropenia, edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, transaminase increased
Serious febrile neutropenia, pneumonia, sepsis
Postmarketing differentiation syndrome, interstitial lung disease, cardiomyopathy
Most common (>=10%) Decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, headache
Serious Sepsis, fracture, cardiac failure, hemorrhage
Pharmacology
Decitabine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, causing hypomethylation and cellular differentiation or apoptosis; cedazuridine inhibits cytidine deaminase in the gastrointestinal tract and liver to increase systemic exposure of orally administered decitabine.
Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the RNA template region of human telomerase (hTR), inhibiting telomerase enzymatic activity and reducing malignant stem and progenitor cell proliferation while inducing apoptotic cell death in MDS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inqovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Rytelo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Inqovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Rytelo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Inqovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Rytelo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InqoviView full Inqovi profile
RyteloView full Rytelo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.